IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/probiotec-ltd" target="_blank" data-smartkarma-citation="entities:12047:1" rel="noopener">Probiotec Ltd (PBP AU)</a> has entered a scheme implementation deed with <a href="https://www.smartkarma.com/entities/pyridam-farma-tbk-pt" target="_blank" data-smartkarma-citation="entities:12900:1" rel="noopener">Pyridam Farma (PYFA IJ)</a> at A$3.00 per share, a 19.0% premium to the undisturbed price (21 December).</li>
<li>Including potential dividends, the total potential offer price is A$3.075 per share. The scheme requires Probiotec shareholders, Pyridam shareholders, FIRB and Indonesia OJK approvals.</li>
<li>The offer is attractive and represents an all-time high. At the last close, the gross spread of the base offer and total potential offer is 3.1% and 5.7%, respectively.  </li>
</ul>



Probiotec Ltd (PBP AU) has entered a scheme implementation deed with Pyridam Farma (PYFA IJ) at A$3.00 per share, a 19.0% premium to the undisturbed price (21 December).
Including potential dividends, the total potential offer price is A$3.075 per share. The scheme requires Probiotec shareholders, Pyridam shareholders, FIRB and Indonesia OJK approvals.
The offer is attractive and represents an all-time high. At the last close, the gross spread of the base offer and total potential offer is 3.1% and 5.7%, respectively.  


Probiotec (PBP AU): Pyridam’s Binding Proposal

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

<ul>
<li>Drugs maker/packager group <strong><a href="https://www.smartkarma.com/entities/probiotec-ltd" target="_blank" data-smartkarma-citation="entities:12047:1" rel="noopener">Probiotec Ltd (PBP AU)</a></strong> has <a href="https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02757332-3A633846" target="_blank" rel="noopener">entered into a Scheme</a> with Indonesia's <strong><a href="https://www.smartkarma.com/entities/pyridam-farma-tbk-pt" target="_blank" data-smartkarma-citation="entities:12900:1" rel="noopener">Pyridam Farma (PYFA IJ)</a></strong>.</li>
<li>Pyridam is offering Probiotec shareholders A$3.00/share (in cash, or a 19% premium to the undisturbed price). Interim and final  dividends up to A$0.035/share and A$0.04/share, respectively, may be added.</li>
<li>It has not been declared final. The Offer has the board's backing. A Scheme Meeting is expected to be held in May with possible completion in early June 2024.</li>
</ul>


Drugs maker/packager group Probiotec Ltd (PBP AU) has entered into a Scheme with Indonesia's Pyridam Farma (PYFA IJ).
Pyridam is offering Probiotec shareholders A$3.00/share (in cash, or a 19% premium to the undisturbed price). Interim and final  dividends up to A$0.035/share and A$0.04/share, respectively, may be added.
It has not been declared final. The Offer has the board's backing. A Scheme Meeting is expected to be held in May with possible completion in early June 2024.


Probiotec (PBP AU) Agrees To Pyridam's Bid

Australia

Probiotec Ltd. manufactures over-the-counter pharmaceuticals and complementary products.  The Company also contract manufactures prescription, over-the-counter, and neutraceutical products for third parties.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Probiotec Ltd (PBP AU)

Probiotec (PBP AU): Pyridam’s Binding Proposal

The offer is attractive and represents an all-time high. At the last close, the gross spread of the base offer and total potential offer (including...

Arun George

Probiotec (PBP AU) Agrees To Pyridam's Bid

A life-time high offer price, board approval, and funding secured. This looks done. Trading at a 6.0%/12.7% gross/annualised spread, including...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)